Liquidity and Management's Plans (Details) (USD $)	1 Months Ended		12 Months Ended											12 Months Ended
	May 31, 2012	Jan. 31, 2012	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010	Dec. 03, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Feb. 24, 2012	Dec. 31, 2009	Nov. 30, 2012 Series A Non-Voting Convertible Preferred Stock [Member]	Dec. 03, 2012 Preferred stock class A [Member]	Dec. 31, 2012 ONSOLIS [Member]	Dec. 31, 2011 ONSOLIS [Member]	Dec. 31, 2010 ONSOLIS [Member]	Dec. 31, 2012 Milestones [Member]	Dec. 31, 2011 Meda license agreement [Member]	Dec. 31, 2010 Meda license agreement [Member]	Dec. 31, 2010 U.S. government's qualifying therapeutic discovery project [Member]	Dec. 31, 2012 Maximum [Member]	Dec. 31, 2012 Minimum [Member]
Liquidity and Management's Plan (Textual) [Abstract]
Net royalties under the Meda agreements			$ 1,082,742	$ 2,716,452	$ 1,884,080									$ 1,100,000	$ 2,700,000	$ 1,900,000		$ 1,000,000	$ 1,000,000
Estimated cost in connection to reformulation project																					800,000	600,000
Deferred Revenue			1,473,479	14,154,720													1,500,000
Non-refundable up-front license payment	15,000,000	30,000,000
Payment received from milestone and royalties																	45,000,000
Sponsored research revenue from the U.S. government's qualifying therapeutic discovery project					244,479															200,000
Company's securities universal shelf registration																					50,000,000
Preferred Stock, par value			$ 0.001	$ 0.001								$ 0.001
Preferred Stock issued													2,709,300
Liquidity and Management's Plan (Additional Textual) [Abstract]
Net proceeds from a private placement offering of Common Stock in March 2011				14,000,000
Exercise of Common Stock warrants			921,019	1,749,259
Contract revenue from licensing and supply agreement				300,000	500,000
Research revenues from various contractor agreements			13,375	227,668	726,948
Exercise of Common Stock options			2,054,100	349,676	97,882
Cash and cash equivalents			63,189,307	10,750,205	18,208,659						23,873,403
Cash from operations			12,187,324	(23,274,994)	(11,682,297)
Stockholders' equity			49,777,213	4,120,393	9,786,330		(10,471,217)	(12,297,063)	(13,545,435)		14,458,299
Net proceeds from registered direct offering of common stock and warrants in April 2010					9,700,000
Company's securities universal shelf registration potential value										40,000,000
Upfront and milestone payments from Endo license agreement			45,000,000
Net proceeds from registered direct offering of Common Stock and newly designated Series			38,400,000
Deferred contract revenue			17,500,000
Common Stock, shares issued			37,497,703	29,577,146		6,791,887
Proceeds from sale of common stock			$ 37,499	$ 29,578		$ 38,400,000